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Abstract
This article summarized findings of current preclinical studies that implemented hydrogen administration, either in
the gas or liquid form, as treatment application for neurological disorders including traumatic brain injury (TBI),
surgically induced brain injury (SBI), stroke, and neonatal hypoxic-ischemic brain insult (HI). Most reviewed studies
demonstrated neuroprotective effects of hydrogen administration. Even though anti-oxidative potentials have been
reported in several studies, further neuroprotective mechanisms of hydrogen therapy remain to be elucidated.
Hydrogen may serve as an adjunct treatment for neurological disorders.
Keywords: Hydrogen, Neuroprotection, Oxidative stress, Reactive oxygen species
Introduction
Traumatic brain injury (TBI) and cerebral vascular
events can be devastating; yet there are few treatments
proven to ameliorate the brain damage and overall out-
come in patients. An ideal neuroprotectant would be
non-toxic, easily administered, permeable at the blood-
brain barrier (BBB), and offer protection at all stages of
injury, including prophylaxis. Hydrogen sulfide (H2S)
has shown some of these properties [1,2]. Its mechan-
isms may be related to the attenuation of reactive oxy-
gen species (ROS) [3], or to its role as a
neuromodulator [4]; however, the use of H2S is contro-
versial because of its toxicity [5] and gasotransmitter
functions [6].
Hydrogen is the most abundant element in the uni-
verse [7]. Room air concentrations of hydrogen gas
higher than 4% (normal air content = 0.000055%) are
explosive, and could cause asphyxiation [8]. Therapeuti-
cally relevant dosages of hydrogen, as used in the fol-
lowing animal studies (range 2%-2.9%), appear to be
well tolerated. Furthermore, 3% hydrogen gas has been
safely and regularly used for human deep-sea divers
without any adverse events [9].
Currently, to our knowledge, there are no FDA
approved therapeutic regimens involving hydrogen gas
or dissolved hydrogen. We sought to analyze recent
available data regarding the use of hydrogen as a
neuroprotectant.
Hydrogen therapy for traumatic brain injury and cerebral
vascular events
Traumatic brain injury
Trauma is the leading cause of death in Americans
younger than 45 years of age, and traumatic brain injury
(TBI) accounts for over 50% of this mortality [10]. Out
of the 1.5 million Americans who sustain a TBI each
year, 230,000 are hospitalized, 80,000 to 90,000 remain
with long-term disabilities, 50,000 die, and the estimated
annual cost exceeds $60 billion [11-13]. To investigate
whether hydrogen (H2) exerts abilities to ameliorate the
outcome after TBI, Ji et al. administered 2% H2 to rats,
which were also subjected to experimental TBI [14].
TBI-challenged rats, that did not inhale H2, presented
with significantly greater brain edema, blood-brain bar-
rier (BBB) permeability, lesion size, and neurological
impairments, than those in the treatment group.
Decreased levels of oxidative products such as
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malondialdehyde (MDA) and 8-iso-prostaglandin F2a
(8-iso-PF2a), were decreased in brain tissues of treated
animals, suggesting that H2 induces neuroprotection by
reducing oxidative stress to the BBB.
Surgical brain injury
Each year, approximately 800,000 patients undergo neu-
rosurgical procedures in the United States [15]. This fig-
ure encompasses emergent as well as planned
procedures. Neurosurgical operations have the potential
to cause unavoidable damage to healthy brain tissue
through application of pressure, tissue stretching,
hemorrhage, and the use of electrocautery [16]. This
form of brain injury occurs regularly, despite of intrao-
perative adjunct treatments such as administration of
steroids and mannitol in both emergent or scheduled
procedures [17]. Even standard microsurgical techniques
have the ability to cause damage to the surrounding
brain tissue, thus leading to early complications such as
edema formation and local ischemia.
To determine the effects of hydrogen treatment fol-
lowing surgically-induced brain injury (SBI), Eckermann
et al. utilized a novel rat model that involved a partial
right frontal lobectomy [18]. The following groups were
compared: rats subjected to sham operation (craniot-
omy), SBI animals that received 2.9% hydrogen, which
was administered concurrently with surgery for a period
of 0.5 hours, and a control group (SBI + room air).
Brain water content and neurological deficits were mea-
sured at 24 hours after SBI. The results demonstrated
that hydrogen treatment significantly decreased the for-
mation of cerebral edema, which resulted in improved
neurobehavioral function; however, the treatment failed
to reduce oxidative stress and cerebral inflammation
(evaluated via Lipid Peroxidase and Myeloperoxidase
assays, respectively) in rats subjected to SBI.
Stroke
Stroke is a leading cause of death and long-term disabil-
ity, particularly in the elderly population [19]. It is asso-
ciated with a 30-day mortality rate of approximately
20% [19]. The prevalence of stroke is expected to
increase significantly as the global population of men
and women - older than 65 years of age - increases con-
tinuously by an estimated 9 million people per year [20].
Consequently, it is most essential to investigate novel
and potentially effective therapeutics to improve the
neurofunctional outcome in patients. The effects of
hydrogen treatment for ischemic stroke have been eval-
uated in an experimental rodent model of transient mid-
dle cerebral artery occlusion (tMCAO) [21]. This model
exerts its damaging effect through focal ischemia and
reperfusion, which generates acute oxidative stress to
the affected brain regions. Under general anesthesia the
rat’s left middle cerebral artery (MCA) was occluded
using a nylon monofilament with a distal silicon rubber
tip. The treatment group inhaled 2% hydrogen gas dur-
ing the entire procedure. Treated and control animals
underwent neurological testing, and were sacrificed at
12 hours, 24 hours, 3 days, and 7 days post-surgery.
Brains were then sectioned and stained with 2,3,5-tri-
phenyltetrazolium chloride (TTC) to label the infarcted
brain area, followed by volumetric computation of the
infarct volume. Observed protective effects of hydrogen
therapy included: decreased infarct volume, maintenance
of body weight after surgery, and improved neurological
function when compared to control animals. Liu et al.
[22] utilized the tMCAO model to evaluate neuropro-
tective effects of intraperitoneally administered hydrogen
saline (1 ml/100 g body weight). The results showed
that hydrogen saline significantly reduced infarct
volume, brain edema, and neurological function when
administered within a 6 hour time window after ische-
mia induction. Hydrogen saline reduced ROS, inflamma-
tion markers, as well as caspase 3 activity in the
ischemic brain [22]. Matchett et al. administered hydro-
gen gas (2.9%) to adult rats that were subjected to
tMCAO [23]. Hydrogen administration showed a ten-
dency to reduce the infarction volume in the treatment
group, when compared to control animals; however,
neurological deficits were similar in both groups.
Furthermore, Chen et al. [24] reported that hydrogen
gas effectively reduced acute hyperglycemia-enhanced
hemorrhagic transformation after focal ischemia in the
rat. Potential mechanisms on how hydrogen gas amelio-
rates hemorrhagic transformation remain to be
investigated.
Oshawa et al. demonstrated that hydrogen selectively
reduced ROS in neuronal tissue cultures [21]. The
effects were demonstrated via electron spin resonance
signals in cells subjected to oxygen glucose deprivation
followed by oxygen glucose reperfusion, which models
cerebral ischemia-reperfusion in vitro [21]. After reper-
fusion, fluoroscopy demonstrated an immediate decrease
in hydroxyl radicals (OH-), and an increase in neuronal
survival at 24 hours, suggesting that hydrogen effectively
protects neurons from oxidative stress-mediated cell
death.
Hemorrhagic stroke is often more severe than
ischemic stroke, and includes intracerebral hemorrhages
(ICH) and subarachnoid hemorrhages (SAH). The mor-
tality rates for ICH and SAH have been reported as 40%
to 50%, and survivors are commonly affected by chronic
morbidity [25]. Furthermore, the aggregate lifetime cost
of hemorrhagic stroke cases has been estimated as high
as $5.6 to $6.0 billion per year [26]. The effects of
hydrogen administration in hemorrhagic stroke models
have been previously reported. In a mouse model that
implemented collagenase-induced ICH, hydrogen ther-
apy was found to significantly reduce cerebral edema
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and neurological deficits at 24 hours after surgery; how-
ever, hydrogen post-treatment showed only a tendency
to improve these outcomes at 72 hours after surgery
[27]. The authors conclude that hydrogen inhalation
exerts an acute neuroprotective effect in mice subjected
to experimental ICH. Similarly to these results, hydro-
gen treatment (2.9% for 2 hours) starting 1 hour after
induction of experimental SAH (endovascular perfora-
tion method), ameliorated brain edema, reduced apopto-
sis, and improved neurological deficits at 24 hours, but
not at 72 hours after surgery [28]. The protective effects
of hydrogen therapy were associated with the reduction
of oxidative injury of lipids, proteins, and DNA.
Neonatal hypoxia-ischemia
Advances in perinatal care and neonatology led to
increased survival of premature infants [29], yet the inci-
dence of brain injury caused by neonatal hypoxia-ische-
mia (HI) remains high [30]. Effective therapeutic
modalities are limited for the treatment of HI. This
form of CNS injury occurs at a very early stage in life. It
is accompanied by a heavy toll on families and signifi-
cant long-term healthcare demands. Since neonates have
an immature free radical buffering system, they are
believed to be more vulnerable to ROS damage.
Hydrogen treatment was associated with improved
outcomes in a model of neonatal hypoxia/ischemia
[31,32]. Cai et al. [32] subjected seven-day old rat pups
to left common carotid artery ligation followed by 90
minutes of hypoxia. Immediately after the HI injury the
pups were placed in chambers containing 2% hydrogen
for 30, 60, and 120 minutes. Twenty-four hours follow-
ing hydrogen therapy, the animals were sacrificed and
the brain damage was assessed with TTC and Nissl
staining, TUNEL, and evaluation of caspase activity.
Hydrogen therapy significantly reduced the number of
TUNEL positive cells, and attenuated caspase activity,
suggesting that hydrogen gas exerts neuroprotective
effects by inhibiting cellular apoptosis after HI. How-
ever, in another study of HI, hydrogen treatment failed
to show neuroprotective effects, possibly as a result of
the severity of the injury [23]. The authors concluded
that hydrogen gas may have a neuroprotective effect
against mild to moderate HI, but loses that effect in
cases of severe HI injury.
Discussion
Despite significant efforts directed towards the develop-
ment of therapies that effectively reduce brain damage,
particularly in TBI, only moderate success has been
reported. So far, most advances involved preventative
behavior modifications, such as wearing seat belts and
helmets when using motor vehicles and motorcycles
[12,13]. Further efforts need to be directed towards the
search of neuroprotective agents that effectively improve
the outcome of patients, even when applied post-injury.
Many approaches have been suggested as post-treat-
ments for CNS injuries such as hypothermia, vitamin E,
hyperbaric oxygen, and numerous medications for
ischemic and hemorrhagic strokes [33,34]. Post-injury
protection reducing subsequent progression of the brain
damage is critical; however, current success has been
limited at best. Continued efforts are warranted to iden-
tify suitable neuroprotective agents that are inexpensive,
easy to administer, and that present high therapeutic
indexes. Increasing evidence suggests that hydrogen may
be such an agent (Table 1). Several studies claim that
hydrogen evokes cellular protection through attenuation
of ROS production following diverse brain injuries. It
has been demonstrated that hydrogen exerts a therapeu-
tic antioxidant effect by selectively reducing hydroxyl
radicals (OH-), which are believed to be potent cytotoxic
ROS, indiscriminately damaging proteins, lipids, and
nucleic acids [21]. Furthermore, no known cellular
detoxification system exists for OH-. Hydrogen also
effectively protects cellular damage to non-neuronal tis-
sues including renal, lung, and myocardial injury [21].
A recent clinical study by Ono et al. [35] showed that
acute treatment with OH- scavengers (Edaravone and
hydrogen) improved MRI indices (accelerated normali-
zation) in patients with brainstem infarction. In fact,
intravenous injection of Edaravone combined with
hydrogen saline showed significantly better results than
administration of Edaravone alone. The effects of hydro-
gen have also been examined in a randomized, double-
blinded, placebo-controlled crossover study implemen-
ted in patients with diabetes mellitus type 2 [36].
Patients that received 900 ml/day of hydrogen-rich
water for 8 weeks showed significant improvements of
LDL cholesterol and urinary 8-isoprostanes. Further
protective effects of hydrogen therapy were found in
patients with mitochondrial myopathies, polymyositis
and dermatomyositis [37].
Importantly, it needs to be determined if hydrogen
treatment alters normal metabolism, since several agents
classified as ROS, such as nitric oxide (NO), have
important cell signaling functions and are regulators of
physiologic responses [21]. It is crucial that the adminis-
tered antioxidant does not disturb these normal cell-sig-
naling pathways. Hydrogen may also function by
preventing break-down of the BBB. The most prominent
and consistent effect is the reduction of cerebral edema
and the improvement of neurological function post-
injury. Hydrogen has several advantages as a potential
antioxidant: it effectively reduces cytotoxic OH- in vivo,
and demonstrates excellent penetration characteristics.
Its ability to enter biomembranes and diffuse into mito-
chondria and cell nuclei render it highly effective as a
powerful antioxidant [21].
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Taken together, hydrogen appears to be a safe thera-
peutic with the ability to attenuate ROS production
after diverse CNS injuries. Furthermore, hydrogen effec-
tively reduced neuronal apoptosis and hemorrhagic
transformation after ischemic brain injury. Its ease of
use and availability will facilitate clinical transition in
the near future; however, further mechanisms of neuro-
protection need to be primarily investigated.
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